Outlook Wealth Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Outlook Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.0% during the first quarter, HoldingsChannel.com reports. The fund owned 334 shares of the biopharmaceutical company’s stock after purchasing an additional 73 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $321,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Meyer Handelman Co. increased its stake in shares of Regeneron Pharmaceuticals by 11.4% in the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after buying an additional 435 shares during the last quarter. Stifel Financial Corp grew its stake in Regeneron Pharmaceuticals by 12.2% in the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after purchasing an additional 3,385 shares in the last quarter. LPL Financial LLC increased its holdings in Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after buying an additional 3,479 shares during the last quarter. Cavalier Investments LLC raised its stake in Regeneron Pharmaceuticals by 88.6% during the third quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after buying an additional 2,084 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after buying an additional 1,221 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now directly owns 18,382 shares in the company, valued at approximately $17,540,472.04. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The disclosure for this sale can be found here. Insiders have sold a total of 11,022 shares of company stock valued at $10,552,991 in the last three months. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Down 0.8 %

NASDAQ REGN traded down $7.48 on Friday, hitting $883.20. 505,652 shares of the company were exchanged, compared to its average volume of 431,865. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The firm has a market capitalization of $96.94 billion, a P/E ratio of 25.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11. The company’s 50 day moving average price is $948.00 and its 200-day moving average price is $893.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the business earned $10.96 earnings per share. The firm’s revenue was up .6% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on REGN shares. Bank of America boosted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Barclays upped their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.